27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
An OTC-listed large-cap biotech is seeking a main exchange listing, and it offers scope for investing in a proven biotech with two commercial partnered products on the market and more in the pipeline.
The IPO Terms
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Copenhagen, Denmark-based GENMAB A/S/S ADR (OTC:GMXAY) has filed for offering 27.80 million American Depository Shares in an initial public offering with the price estimated at $18.11.
Each ADS share represents the right to receive one-tenth of an ordinary share. The shares of Genmab are currently listed on the Nasdaq Copenhagen and the ADSs on the OTC market in the U.S.
Genmab has applied for listing its ADS shares on the Nasdaq under the ticker symbol GMAB.
Bank of America Merrill Lynch, Morgan Stanley, Jefferies are the joint lead managers for the offering, while Guggenheim Securities and RBC Capital Markets are the co-managers.
The Company
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Genmab is an international biotech company specializing in antibody-therapeutics for the treatment of cancer and other diseases. The two marketed partnered products are Darzalex for the treatment of certain indications of multiple myeloma and Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
The company has five proprietary product candidates in the pipeline and about 20 proprietary and partnered pre-clinical programs.
Source: F-1/A filing
The Finances
Genmab's 2018 revenues climbed 28% to $455.28 million, and it reported 33% net profit growth to $221.55 million. Over the first three months of 2019 the company's revenues and net profit declined about 13% and 64%, respectively to $88.95 million and $10.87 million.
Related Links:
DouYu International IPO: What You Need To Know
A Halftime Report Of The IPO Market In 2019
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.